"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
| Descriptor ID |
D017277
|
| MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
| Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 1 | 3 | 4 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 5 | 8 |
| 2004 | 2 | 8 | 10 |
| 2005 | 7 | 6 | 13 |
| 2006 | 3 | 6 | 9 |
| 2007 | 4 | 12 | 16 |
| 2008 | 4 | 6 | 10 |
| 2009 | 4 | 2 | 6 |
| 2010 | 7 | 15 | 22 |
| 2011 | 10 | 11 | 21 |
| 2012 | 2 | 14 | 16 |
| 2013 | 9 | 14 | 23 |
| 2014 | 7 | 12 | 19 |
| 2015 | 15 | 22 | 37 |
| 2016 | 16 | 8 | 24 |
| 2017 | 10 | 18 | 28 |
| 2018 | 13 | 15 | 28 |
| 2019 | 14 | 21 | 35 |
| 2020 | 15 | 20 | 35 |
| 2021 | 23 | 15 | 38 |
| 2022 | 11 | 8 | 19 |
| 2023 | 1 | 6 | 7 |
| 2024 | 9 | 13 | 22 |
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Physician-Patient Communication about Novel Drugs and High-Risk Medical Devices. Med Decis Making. 2025 02; 45(2):156-167.
-
Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022. BMC Med. 2024 Dec 18; 22(1):587.
-
Magnitude of effect of low dose colchicine, a newly food and drug administration approved treatment for stroke prevention. J Stroke Cerebrovasc Dis. 2025 Feb; 34(2):108186.
-
Fear of missing out: Drug availability in the United States vs Canada. J Manag Care Spec Pharm. 2024 Dec; 30(12):1349-1354.
-
Spending on anticancer drugs among Medicare beneficiaries: Analyzing predictors of drug expenditures. J Cancer Policy. 2024 Dec; 42:100509.
-
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement. Alzheimers Dement. 2024 Nov; 20(11):8162-8171.
-
Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs? Curr Oncol. 2024 09 18; 31(9):5599-5607.
-
Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review. JAMA Oncol. 2024 Aug 01; 10(8):1055-1059.
-
Brief of over 300 reproductive health researchers as Amici Curiae in FDA v. Alliance for Hippocratic Medicine. Perspect Sex Reprod Health. 2024 Dec; 56(4):320-328.
-
The landscape of checkpoint inhibitors in oncology. Eur J Cancer. 2024 Sep; 209:114240.